Companies link to combine TMR (transmyocardial revascularisation) and gene therapy:
This article was originally published in Clinica
Executive Summary
Cardiac laser developer Cardiodyne and biopharmaceutical company Endovasc are to co-develop new treatments for angina, heart failure and other conditions which combine transmyocardial revascularisation (TMR) and liposomal therapeutics. Irvine, California-based Cardiodyne, which is developing a system which combines TMR with ECG-synchronised gene injection, will have certain rights to products developed through the collaboration.